- Home
- JL vs KAPA Comparison
JL vs KAPA Comparison
Compare JL & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- KAPA
- Stock Information
- Founded
- JL 1985
- KAPA 2013
- Country
- JL Hong Kong
- KAPA United States
- Employees
- JL N/A
- KAPA N/A
- Industry
- JL
- KAPA
- Sector
- JL
- KAPA
- Exchange
- JL NYSE
- KAPA NYSE
- Market Cap
- JL 10.0M
- KAPA 9.1M
- IPO Year
- JL 2024
- KAPA 2024
- Fundamental
- Price
- JL $6.04
- KAPA $0.66
- Analyst Decision
- JL
- KAPA Strong Buy
- Analyst Count
- JL 0
- KAPA 3
- Target Price
- JL N/A
- KAPA $8.33
- AVG Volume (30 Days)
- JL 18.4K
- KAPA 2.2M
- Earning Date
- JL 07-07-2025
- KAPA 08-23-2025
- Dividend Yield
- JL N/A
- KAPA N/A
- EPS Growth
- JL N/A
- KAPA N/A
- EPS
- JL 0.54
- KAPA N/A
- Revenue
- JL $32,831,195.00
- KAPA N/A
- Revenue This Year
- JL N/A
- KAPA N/A
- Revenue Next Year
- JL N/A
- KAPA N/A
- P/E Ratio
- JL $11.29
- KAPA N/A
- Revenue Growth
- JL 7.72
- KAPA N/A
- 52 Week Low
- JL $2.33
- KAPA $0.40
- 52 Week High
- JL $13.41
- KAPA $4.00
- Technical
- Relative Strength Index (RSI)
- JL 66.11
- KAPA N/A
- Support Level
- JL $5.63
- KAPA N/A
- Resistance Level
- JL $6.43
- KAPA N/A
- Average True Range (ATR)
- JL 0.41
- KAPA 0.00
- MACD
- JL -0.04
- KAPA 0.00
- Stochastic Oscillator
- JL 71.08
- KAPA 0.00
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.